Beam Therapeutics (BEAM) Q1 2026 earnings summary

Executive summary

• Achieved $31.7 million in license and collaboration revenue for Q1 2026, up from $7.5 million year-over-year, driven by a $25 million milestone from the Lilly Agreement.

• Net loss narrowed to $94.3 million from $108.3 million year-over-year, reflecting higher revenue and controlled expenses.

• Advanced clinical programs in sickle cell disease (risto-cel), alpha-1 antitrypsin deficiency (BEAM-302), and glycogen storage disease Ia (BEAM-301), with positive clinical updates and regulatory progress.

• Achieved significant clinical milestones, including strong BEAM-302 Phase 1/2 data in AATD and publication of risto-cel BEACON trial results in NEJM.

• Maintains robust cash position, supporting operations into mid-2029.

Financial highlights

• License and collaboration revenue increased by $24.3 million year-over-year, primarily from a Lilly milestone.

• Research and development expenses rose to $104.5 million from $98.8 million, mainly due to increased headcount and milestone payments.

• General and administrative expenses increased to $34.4 million from $27.9 million, driven by higher personnel and legal costs.

• Net loss per share improved to $(0.91) from $(1.23) year-over-year.

• Cash, cash equivalents, and marketable securities totaled $1.2 billion as of March 31, 2026, unchanged from December 31, 2025.

Outlook and guidance

• Cash runway expected to fund operations through mid-2029, covering key clinical milestones and anticipated product launches.

• Plans to submit a biologics license application for risto-cel by year-end 2026.

• Anticipates initiating pivotal cohort for BEAM-302 in H2 2026 and reporting initial BEAM-301 data in 2026.

• IND filing for BEAM-304 in PKU and initial BEAM-301 data in GSDIa anticipated in 2026.

• Expects continued increases in operating expenses as clinical and manufacturing activities expand.